RxDoctor Payments Data

Brian Flyer, MD

Internal Medicine · Beverly Hills, CANPI 1962594101

Payments from drug & device makers

$3,773in general payments, 2019–2025

Across 97 payments — averaging $38.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • Novartis$412
  • Pfizer$365
  • AstraZeneca$240
  • Johnson & Johnson$188
  • Boehringer Ingelheim$182
  • plus $1K from 15 others

What the payments were for

  • Consulting fees$1,20032%
  • Food & beverage$2,44465%
  • Education$1293%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,773 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$42,701
Medicare patients
119
Services billed
483

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan30$33,662
JardianceEmpagliflozin30$26,529
EliquisApixaban41$24,432
OzempicSemaglutide22$19,147
FarxigaDapagliflozin Propanediol15$8,122
MyrbetriqMirabegron13$7,763
Duloxetine Hcl43$1,634
Sumatriptan Succinate21$1,062
Estradiol (Twice Weekly)Estradiol12$940
Armour ThyroidThyroid,pork14$914
Levothyroxine Sodium113$872
Atorvastatin Calcium82$807
Febuxostat15$757
Metformin Hcl68$619
Quetiapine Fumarate17$560

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$412$33,66230 claims
Boehringer IngelheimJardiance$182$26,52930 claims
PfizerEliquis$365$24,43241 claims
Novo NordiskOzempic$76$19,14722 claims
AstraZenecaFarxiga$240$8,12215 claims
Astellas Pharma US IncMyrbetriq$159$7,76313 claims
AbbVieArmour Thyroid$146$91414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →